Trial · NCT07913022
Early Healing of Apical Periodontitis After Root Canal Treatment With Bioceramic and Calcium Hydroxide Medicaments: Evaluation Using PAI and ImageJ
NCT07913022, Not applicable, Active not recruiting, Hasanuddin University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Early Healing of Apical Periodontitis After Root Canal Treatment With Bioceramic and Calcium Hydroxide Medicaments: Evaluation Using PAI and ImageJ. Trials, record NCT07913022. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913022
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Early Healing of Apical Periodontitis After Root Canal Treatment With Bioceramic and Calcium Hydroxide Medicaments: Evaluation Using PAI and ImageJ
- NCT number
- NCT07913022
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Hasanuddin University
- Conditions
- Apical Periodontitis, Root Canal Treatment, Intracanal Medicaments
- Interventions
- Bioceramic Intracanal Medicament, Calcium Hydroxide Intracanal Medication
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Periapical Index (PAI) Score From Baseline to 3-Month Follow-up | Baseline to 3 months after treatment | Changes in Periapical Index (PAI) scores will be assessed by comparing periapical dental radiographs obtained at baseline and at the three-month follow-up. Radiographs will be evaluated by a blinded outcomes assessor. Changes in PAI scores will be compared between the bioceramic and calcium hydroxide groups. |
| Primary | Change in Periapical Lesion Area From Baseline to 3-Month Follow-up | Baseline to 3 months after treatment | Changes in periapical lesion area will be measured using ImageJ software on periapical dental radiographs obtained at baseline and at the three-month follow-up. Radiographs will be obtained using the paralleling technique and evaluated by a blinded outcomes assessor. Changes in lesion area will be compared between the bioceramic and calcium hydroxide groups. |
| Primary | Change in Periapical Lesion Density From Baseline to 3-Month Follow-up | Baseline to 3 months after treatment | Changes in periapical lesion density will be assessed quantitatively using ImageJ software on periapical dental radiographs obtained at baseline and at the three-month follow-up. Radiographs will be evaluated by a blinded outcomes assessor, and changes will be compared between the bioceramic and calcium hydroxide groups. |
| Primary | Change in Periapical Lesion Fractal Dimension From Baseline to 3-Month Follow-up | Baseline to 3 months after treatment | Changes in the fractal dimension of periapical lesions will be measured using ImageJ-based image analysis on periapical dental radiographs obtained at baseline and at the three-month follow-up. Radiographs will be evaluated by a blinded outcomes assessor, and changes will be compared between the bioceramic and calcium hydroxide groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913022
GET https://conductscience.org/api/trials/v1/NCT07913022/registered